While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

Low rates of retained gastric contents were seen in endoscopy patients on GLP-1 receptor agonists ( RAs), a retrospective ...

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

Discover how food brands can adapt to the rising GLP-1 trend. As weight-loss drugs reshape consumer habits, learn which ...

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump the widely prescribed metformin for ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...

For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using ...

Consumers are the only ones struggling to pay the rising prices of popular GLP-1 drugs, as states like Connecticut see ...

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an increased risk for gastroesophageal reflux disease (GERD) and its complications compared ...

“This is the first major study to compare the effect of two common diabetes treatments — GLP-1 medicines and metformin — on dementia risk, using health records from more than 174,000 people. The ...